JP2014510152A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510152A5
JP2014510152A5 JP2014504014A JP2014504014A JP2014510152A5 JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5 JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5
Authority
JP
Japan
Prior art keywords
formulation
viscosity
acetate
reduced
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/032464 external-priority patent/WO2012141978A2/en
Publication of JP2014510152A publication Critical patent/JP2014510152A/ja
Publication of JP2014510152A5 publication Critical patent/JP2014510152A5/ja
Pending legal-status Critical Current

Links

JP2014504014A 2011-04-07 2012-04-06 粘度が低減された処方物 Pending JP2014510152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473123P 2011-04-07 2011-04-07
US61/473,123 2011-04-07
PCT/US2012/032464 WO2012141978A2 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (2)

Publication Number Publication Date
JP2014510152A JP2014510152A (ja) 2014-04-24
JP2014510152A5 true JP2014510152A5 (https=) 2015-05-21

Family

ID=47009919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504014A Pending JP2014510152A (ja) 2011-04-07 2012-04-06 粘度が低減された処方物

Country Status (12)

Country Link
US (1) US20140044727A1 (https=)
EP (1) EP2694708A4 (https=)
JP (1) JP2014510152A (https=)
KR (1) KR20140066124A (https=)
CN (1) CN103582724A (https=)
AU (1) AU2012243126A1 (https=)
BR (1) BR112013025845A2 (https=)
CA (1) CA2832560A1 (https=)
EA (1) EA201391489A1 (https=)
IL (1) IL228626A0 (https=)
SG (1) SG193964A1 (https=)
WO (1) WO2012141978A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501364A1 (en) * 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
SG193963A1 (en) * 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity
EA201590061A1 (ru) * 2012-06-21 2015-05-29 Юсб Фарма С.А. Фармацевтическая композиция
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
KR20180037275A (ko) 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
CN105733250B (zh) * 2016-05-04 2017-12-26 山东省药学科学院 一种交联聚谷氨酸悬浮液及其制备方法与应用
ES2933808T3 (es) * 2017-01-11 2023-02-14 Celltrion Inc Fórmula líquida estable
SI4190355T1 (sl) * 2017-04-28 2025-02-28 Amgen Inc. Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体の製剤および抗lag3抗体と抗pd-1抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
BR112019025736A2 (pt) 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
CN113660927A (zh) * 2019-04-23 2021-11-16 安进公司 使用低分子量聚乙烯吡咯烷酮(pvp)降低高浓度蛋白质配制品的黏度
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20050164929A1 (en) * 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
CA2503946C (en) * 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
AU2006296399B2 (en) * 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2205280B1 (en) * 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
BR112012013093A2 (pt) * 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
BR112012027828A2 (pt) * 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína

Similar Documents

Publication Publication Date Title
JP2014510152A5 (https=)
JP2014516924A5 (https=)
RU2020123963A (ru) Стабилизированные препараты, содержащие антитела против ngf
JP2013517277A5 (https=)
JP2020537520A5 (https=)
JP2013543505A5 (https=)
IL283424B2 (en) Stabilized formulations that include antibodies against the interleukin receptor (il-4r)
RU2016129624A (ru) Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
RU2013155695A (ru) Препараты антител против с-мет
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
JP2017515909A5 (https=)
MX363226B (es) Formulaciones de anticuerpos.
JP2013535190A5 (https=)
JP2014522843A5 (https=)
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
EA200970880A1 (ru) Стабильные композиции на основе антител
RU2015123476A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
JP2014502955A5 (https=)
AR088455A1 (es) Anticuerpos que antagonizan cd40l
HRP20192346T1 (hr) Molekule anti-lag-3 antitijela i njihove uporabe
FI3355919T3 (fi) Yhdistelmähoito ihmisen kasvu- ja erilaistumistekijä 15:n (GDF-15) inhibiittoreita ja immuunitarkistuspiste-estäjiä käyttämällä
JP2016539096A5 (https=)
HRP20191199T1 (hr) Formulacije protutijela anti-prolaktinskog receptora